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Background: Neuron specific enolase (NSE) is a recognized biomarker for assessment of neurological outcome
after cardiac arrest, but its reliability has been questioned. Our aim was to investigate what influence storage of
samples and choice of measuring methods may have on levels of NSE in peripheral blood.
Methods: Two serum samples were drawn simultaneously from 51 hypothermia treated cardiac arrest patients.
One sample (original sample) was analysed when collected, using the Diasorin-method (LIAISON®NSE, LNSE). The
other sample was frozen, stored at −70°C (stored sample), and reanalysed in the same laboratory 4–7 years later
using both the Diasorin method and a Roche-method (NSE Cobas e601, CNSE). In addition, a comparison of the
two methods was performed on 29 fresh samples.
Results: The paired NSE results in original and stored samples were not significantly different, using the LNSE-method.
The two methods produced significantly different results (p < 0.0001) on the paired, stored samples, with the CNSE
method yielding higher values than the LNSE-method in 96% of samples. The CNSE method resulted in 36% higher
values on average. In the method comparison on fresh samples, the CNSE-method generated on average 15% higher
values compared to the LNSE-method, and the difference between the paired results was significant (p < 0.0001).
Conclusion: The CNSE method generated consistently higher NSE-values than the LNSE method and this difference
was more pronounced when frozen samples were analysed. Tolerability for prolonged freezing was acceptable.
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Neuron specific enolase (NSE) is a dimeric intracellular
glycolytic enzyme, comprised of two subunits, γγ or αγ.
It is present in neurons and in other cells of neuroecto-
dermal origin, but is also found in erythrocytes [1] and
platelets [2]. Its half-life in serum is estimated to be 30 h
[3]. Haemolysis produces an increase in NSE in serum
in proportion to the degree of haemolysis [1,3].
Serum NSE is the only biochemical marker of brain
injury that has been incorporated into guidelines for
neurological prognostication after cardiac arrest [4]. The
proposed cut-off value (33 μg/L) was based primarily
on studies of cardiac arrest patients not treated with
therapeutic hypothermia [5-9]. Recent studies evaluating* Correspondence: malin.rundgren@skane.se
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unless otherwise stated.NSE as a prognostic marker in hypothermia treated
cardiac arrest patients have shown divergent results;
while some studies support the proposed cut-off value
[10,11], other studies do not [12-15]. As a consequence,
the use of NSE as a biomarker to predict outcome after
cardiac arrest has been questioned. Little is known
about the influence of hypothermia on the release-curve
and turnover of NSE. Also, the influence of handling and
storage of samples need to be further investigated.
Currently, there are several commercially available NSE
immunoassays from different manufacturers and no com-
mon standard. Several analytical as well as pre-analytical
factors may affect the measured result [16]. For instance,
based on the interference of NSE from erythrocytes it has
been recommended that an index of haemolysis to be
performed prior to analysing the sample [1], and this is
not routinely done. Also, determination of NSE was
performed on fresh samples in some studies [6,17] and
retrospectively using frozen samples in other [13,18,19],ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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no effect on NSE-levels by the storing of serum for up
to 9 months [1], but the effect of long term storing
has not been investigated. In addition, methodological
differences, such as differences in antibody binding-
site and/or specificity and calibration errors may affect
the measured levels of NSE [16]. Since methodological
differences and analytical errors may explain some of
the discrepancies regarding NSE results, several authors
have advised against the use of the previously specified
cut-off level of NSE for determination of poor prognosis
after cardiac arrest [20-22].
In order to assess the effect of long term storing, we
analysed NSE in serum on original fresh samples, and
4–7 years later on frozen and stored samples collected
simultaneously. We also compared two automated
immuno-assays for NSE from two different manufacturers,
using both fresh and long term frozen samples.
Methods
This study was performed at Skane University Hospital,
Lund, Sweden, on samples collected from hypothermia
treated cardiac arrest patients in the intensive care unit
between November 2003 and December 2006. The study
was approved by the Regional Ethical Review Board at
Lund University (411/2004), and informed consent
was sought from next of kin or, retrospectively, from
the patient. The method comparison on fresh venous
samples utilized anonymized patient material, and consent
was waived.
Study samples
Parallel samples from 51 patients with a mean age
63.8 +/−16,0 years, were analysed. Thirty-three of the
patients (65%) were male. All patients were treated
with therapeutic hypothermia at 33°C for 24 hours
after cardiac arrest with a controlled rewarming phase
of 8 hours. Thirty-four patients had cardiac arrest of
cardiac origin (67%). Sixteen of 51 patients (31%) remained
unconscious until death and a total of 18 patients died
during the 6 months follow up (35%).
Serial serum samples from hypothermia treated cardiac
arrest patients were collected during the first 72 h after
cardiac arrest. Two arterial blood samples from each
patient were collected 48 h after the cardiac arrest. The
first sample (the original sample) was centrifuged and
kept refrigerated if analysed within 24 h, otherwise the
sample was frozen (−20°C) and analysed within a week.
The simultaneously collected second serum sample was
centrifuged and frozen at −70°C for later analysis (stored
sample). The stored samples were thawed once and
aliquoted during storage. The samples were reanalysed
after 4–7 years of storage. Patients with intraaortic
balloon-pump counter-pulsations (IABP) were excludedfrom this study because of the risk for low-grade intra-
vascular haemolysis. All samples with visible haemolysis
were discarded on arrival at the laboratory.
In addition, 29 fresh venous serum samples were used
in the study. These fresh samples were aliquoted in 2
portions and stored (less than one week) at −20°C until
analysis.
NSE analysis
All samples were analysed at the Clinical Chemistry
Laboratory, Skane University Hospital, Lund, Sweden.
Determination of NSE in the original samples was per-
formed using the LIAISON®NSE, DiaSorin S.p.A, Saluggia,
Italy. Detection limit and reference interval for this method
was 0.04 μg/L and <18.3 μg/L respectively. The coefficient
of variation (CV) for the analysis method was 7%.
The stored samples and the fresh venous samples were
analysed using two different methods, the LIAISON®NSE
and the NSE Cobas e601, Roche Diagnostics, Mannheim,
Germany. Detection limit and reference interval for this
method was 0.05 μg/L and <17 μg/L respectively. The CV
for the analysis method was 4%.
The LIAISON® NSE method is a fully automated mono-
clonal double (sandwich) chemiluminescence immuno-
assay, where the serum is incubated with an antibody
coated magnetic particle and a luminescence-labelled
tracer. The resulting luminescence is indicative of the
amount of NSE in the sample. The result is presented
in μg/L. (Package insert LIAISON® NSE, DiaSorin, ref
314561).
The NSE Cobas e601 method is a fully automated
electrochemiluminescence immunoassay, where the NSE
in the sample reacts with a biotinylated monoclonal
NSE-specific antibody and a ruthenium labelled NSE –
specific monoclonal antibody. After addition of strepta-
vidin –coupled micro particles the antigen/antibody
complex is detected using chemiluminescence. The
result is determined via an instrument specific calibra-
tion curve and presented in μg/L. (Package insert NSE,
Roche 2010–03).
According to the manufacturers, both analyses measure
the γ subunit of NSE.
Statistics
Patient characteristics are presented as numbers and
percentages. The NSE results were not normally distrib-
uted, thus, data are presented as median, interquartile
range (IQR) and range.
Three comparisons of paired samples were made: first
between the paired original and stored samples using
the LIAISON®NSE analysis method, second between
LIAISON®NSE and Cobas e601on the stored samples
and third, between LIAISON®NSE and Cobas e601 on
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of the three comparisons. Bias, limits of agreement and
95% confidence intervals were calculated. The difference
between the paired samples were analysed using Students
t-test for paired data or Wilcoxon matched sign rank test
according to normality distribution.
Correlation, linearity and the equation of the line were
produced for the three comparisons. GraphPad Prism
5.0 (GraphPad Software, Inc. CA, US) was used for the









Figure 2 NSE measured using LIAISON®NSE on original and
stored samples with line of equity.Results
Results for NSE in the paired original and stored samples
with the LIAISON®NSE method
The median value for NSE in the original samples
according to the LIAISON®NSE method was 13.9 μg/L
(IQR 10.9-20.5 μg/L, range 6.5-169.7 μg/L). The median
NSE value in the stored samples was 14.3 μg/L (IQR 11.1-
23.0 μg/L, range 6.5-172.8 μg/L). The differences between
the paired original and stored samples were normally
distributed with a mean difference of −1.2 μg/L +/−4.8 μg/
L (p = 0.12). Figure 1 shows the Bland–Altman plot of the
samples. NSE was higher in 34/51 (67%) stored samples
compared to the original ones. The correlation coefficient
was r = 0.89 (95% CI 0.80 to 0.93) (p < 0.0001), (Figure 2).
The equation of the line was y = 1.01 x +0.9 with a 95% CI
































Figure 1 Bland-Altman plot showing the difference in NSE
between the original and stored samples, simultaneously
collected from the same individual on the y-axis, versus the
mean between the original and stored NSE values on the
x-axis. The solid line denotes the mean difference between the
analyses and the hatched line the upper and lower 1.96 SD lines.
All analyses were made using the LIAISON®NSE analysis method.increase of 1% (95% CI −4 to +6%) for stored samples over
the whole range of examined values.
Results for NSE with the LIAISON®NSE and the NSE Cobas
e601 methods on stored samples
The median NSE-level in stored samples according to
the NSE Cobas e601 method was 16.3 μg/L (IQR 11.8-
28.5 μg/L, range 0.5-231.2 μg/L). The mean difference
between LIAISON®NSE and the NSE Cobas e601 methods
on the stored samples was −5.4 μg/L, (SD 9.5 μg/L), with
95% limits of agreement +/−19.4 μg/L (Figure 3).
The differences between the paired NSE results were not
normally distributed. The difference between the paired
data was significant (p < 0.0001). The NSE Cobas e601
method showed consistently higher NSE values than the
LIAISON®NSE method, with a higher value in 49/51 (96%)
of samples. The correlation coefficient was r = 0.97 (CI
0.95-0.98, p < 0.0001). Figure 4 shows the scatter of sam-
ples and the assessed linearity. The equation of the line
was y = 1.36 × −3.4 with a 95% CI for the slope of 1.33 to
1.38, which can be translated into a 36% (95% CI 33–38%)
increase in NSE level using the NSE Cobas e601 method.
Results for NSE with the LIAISON®NSE and the NSE Cobas
e601 methods on fresh venous samples
The median NSE-values for the fresh venous samples
were 12.0 μg/L (IQR 8.2-18.8, range 5.4-217.3 μg/L) and
14.0 μg/L (IQR 8.5-23.5, range 6.1-247.0 μg/L) for the
LIAISON®NSE- and the NSE Cobas e601 -methods
respectively. The mean difference between the two
methods was −5.2 μg/L, (SD 8.5 μg/L), with 95% limits
of agreement +/−16.3 μg/L (Figure 5).






























Average LIAISON®NSE Cobas e601 (µg/L)
Figure 3 Bland-Altman plot showing the difference between
the stored samples analysed using the LIAISON and the NSE
Cobas e601 respectively. The samples were exposed to identical
preanalytical conditions. The difference between the NSE levels
analysed on the LIAISON®NSE and the NSE Cobas e601 are shown
on the y-axis and the mean between the LIAISON®NSE and the
NSE Cobas e601 NSE levels on the x-axis. The solid line denotes the
mean difference between the analyses and the hatched line the














Figure 4 NSE measured using stored samples and the
LIAISON®NSE and the NSE Cobas e601 respectively, with line
of equity.




































Figure 5 Bland-Altman plot showing the difference between
the fresh samples analysed using the LIAISON®NSE and the NSE
Cobas e601 respectively. The analysed samples were exposed to
identical Preanalytical conditions. The difference between the NSE
levels analysed on the LIAISON®NSE and the NSE Cobas e601 are
shown on the y-axis and the mean between the LIAISON®NSE and
the NSE Cobas e601 NSE levels on the x-axis. The solid line denotes
the mean difference between the analyses and the hatched line the
upper and lower 1.96 SD lines.
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venous samples were not normally distributed. The differ-
ence between the paired data was significant (p < 0.0001).
The NSE Cobas e601method showed higher NSE values
than the LIAISON®NSE method in 25/29 (86%) of the
samples.
The correlation coefficient between was r = 0.99
(95% CI 0.97 to 0.99). The equation of the line was
y = 1.15 × - 0.1, CI 1.13- 1.17, which can be translated
into a 15% (95% CI 13–17%) increase in NSE level
using the NSE Cobas e601 method (Figure 6).
Discussion
The main finding of this study is that there were significant
differences in NSE results between the two measuring
methods, the NSE Cobas e601 consistently showing higher
values than the LIAISON®NSE, on fresh (15%) as well as on
stored (36%) samples.
The samples stored over a prolonged period of time
(4–7 years) showed a minor NSE increase (mean 1.2 μg/L)
as compared to the original samples, and a non-significant
difference between the paired data. This is in keeping with
the results from a previous study where samples frozen up
to 9 months were investigated [1]. Despite this, the scatter
of the paired results was substantial in some patients with
occasional values diverging as much as 18 μg/L without a


























Figure 6 NSE measured using fresh samples and the
LIAISON®NSE and the NSE Cobas e601 respectively, with
line of equity.
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and 2). Thus, long-term storage may lead to significantly
altered levels of NSE on an individual sample level. This is
a relevant concern since batch analysis of stored samples
is sometimes used to eliminate the risk of clinicians being
biased by the NSE results. Such a strategy is used in the
Target Temperature Management after cardiac arrest trial
(TTM-trial) [23]. As part of the trial, NSE will be evalu-
ated as a prognostic marker after cardiac arrest, including
the potential influence of temperature [24].
In the comparisons between the LIAISON®NSE and
the NSE Cobas e601 methods on stored and fresh
samples respectively, the correlations between the NSE
results from the two methods were good. The correlation
coefficients were 0.97-0.99, which was similar to the
correlation coefficients noted by Stern [16]. However,
the Roche method generated consistently higher results
compared to the DiaSorin method in both the fresh
venous samples and in the stored samples. An interesting
finding was that the results produced by the two methods
differed more when stored samples were analysed as
compared to the fresh venous samples. We speculate
that sample integrity may have been affected by the
freeze-thaw-cycle and storage and that the sensitivity
for decreased sample integrity may differ between the
two analytical methods.
The discrepancies in results between the DiaSorin and
the Roche methods are highly relevant with regards to
the use of NSE to assess neurological outcome after
cardiac arrest. In the AAN guidelines [4], mainly based
on the PROPAC I study [5], a cut-off of 33 μg/L at24–72 hours after cardiac arrest was considered strong
evidence for a poor prognosis [4,5]. In the PROPAC I
study the Sangtec/LIAISON method was used [25]. In a
recent study, the LIAISON®NSE and the CanAg®NSE were
compared in two laboratories with substantial differences
in results [26]. These results in combination with our
findings strengthen the conclusion that a universal cut-
off-value for NSE should not be used for prognostication
purposes and highlights the need for standardisation. In
our opinion, biomarkers including NSE cannot constitute
the sole foundation for withdrawal of life supportive ther-
apy [27]. NSE should rather be regarded as an adjunct in
prognostication after cardiac arrest as part of a multi-
modal approach [15,20,28]. Although the absolute values
apparently depend on the analytical method, the typical
release curve of NSE after cardiac arrest is probably not
affected [11,12], and serial measurements are recom-
mended to increase reliability in predictions.
Measurement of free haemoglobin reduces the risk of
overestimating NSE-levels in samples where haemolysis
occurred during sampling, transport or sample handling.
On Cobas e601 the presence of haemolysis is automatically
assessed in each sample, which is discarded if haemolysis
exceeds a defined threshold value. In a cardiac arrest
population, patients with intra-aortic balloon pumps (IABP)
may have on-going low-grade haemolysis. Since the half-
life of free haemoglobin is approximately 2–4 hours [29],
considerably shorter than the 30 hour half-life of NSE [3],
an accumulation of NSE relative to free haemoglobin may
occur over time. As a consequence, the measured value of
NSE may be inappropriately increased beyond the time-
point where free haemoglobin is no longer detectable in
the sample. This is a cause of concern when using NSE
for prognostication after cardiac arrest. In support for this
reasoning, high NSE-levels, unrelated to detectable brain
injury was found in patients undergoing coronary surgery,
where the haemolysis was caused by cardiopulmonary
bypass and blood-collection devices [3].
Limitations
This is a pilot study using a small number of samples, but
still it illuminates the risk of recommending strict cut-off
levels for NSE, without carefully addressing potential
methodological problems and specifying the measuring
method as well as sample handling and storage.
This study was not designed for prognostication pur-
poses; rather we aimed at addressing potential confounders
when using NSE as part of a prognostic model. Due to the
design of the study, we consider it inappropriate to disclose
sensitivity/specificity or cut-off values for a poor outcome.
In the study we have tried to reduce the effect of prea-
nalytical error by using paired blood-samples collected
by the same personnel and handled in the same way en
route to the laboratory (the original and stored samples),
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ples were made on identical samples, thereby eliminating
differences in sample handling. All determinations of
NSE were performed at the same laboratory, to eliminate
the effect of inter-laboratory variation [30]. When com-
paring published results using NSE as a biomarker for
neuronal injury, variability in results may also include
inter-laboratory variation, which was not addressed in
the current study.
Conclusions
There are two main findings in this study; first that frozen
NSE samples remained relatively stable during long term
storage, and second that there was a consistent and sig-
nificant difference between the LIAISON®NSE and the
NSE Cobas e601 method, with the latter showing consist-
ently higher values in both fresh and stored samples. NSE
should be further evaluated as a prognostic biomarker
after cardiac arrest and in parallel an international stand-
ard should be defined.
Abbreviations
AAN: American Academy of Neurology; IABP: Intra aortic balloon-pump
counter-pulsations; NSE: Neuron specific enolase.
Competing interest
The authors declare that they have no competing interests.
Authors’ contributions
MR and HF treated patients in ICU. TC was responsible for prognostication
and follow up of patients. AI performed NSE analyses. MR was the main
writer but all authors participated in study design and draft of the
manuscript. All authors read and approved the final manuscript.
Acknowledgement
Sources of support: Skane county council’s research and development
foundation.
Author details
1Department of Clinical Sciences, Division of Anaesthesia and Intensive Care,
Lund University, Lund, Sweden. 2Department of Clinical Sciences, Division of
Neurology, Lund University, Lund, Sweden. 3Department of Laboratory
Medicine, Division of Clinical Chemistry and Pharmacology, Lund University,
Lund, Sweden. 4Department of Intensive and Perioperative Care, Skane
University Hospital, Lund, 221 85 Lund, Sweden. 5Center For Resuscitation
Science, Skane University Hospital, Lund, Sweden.
Received: 11 September 2014 Accepted: 3 October 2014
Published: 15 October 2014
References
1. Ramont L, Thoannes H, Volondat A, Chastang F, Millet M, Maquart F: Effects
of hemolysis and storage condition on neuron-specific enolase (NSE) in
cerebrospinal fluid and serum: implications in clinical practice. Clin Chem
Lab Med 2005, 43:1215–1217.
2. Marangos P, Campbell I, Schmechel D, Murphy D, Goodwin F: Blood
platelets contain a neuron-specific enolase subunit. J Neurochem 1980,
34:1254–1258.
3. Johnsson P, Blomquist S, Luhrs C, Malmkvist G, Alling C, Solem J, Stahl E:
Neuron-specific enolase increases in plasma during and immediately
after extracorporeal circulation. Ann Thorac Surg 2000, 69:750–754.
4. Wijdicks E, Hijdra A, Young G, Bassetti C, Wiebe S: Quality Standards
Subcommittee of the American Academy of Neurology. Practice
parameter: prediction of outcome in comatose survivors after
cardiopulmonary resuscitation (an evidence-based review): report of theQuality Standards Subcommittee of the American Academy of
Neurology. Neurology 2006, 67:203–210.
5. Zandbergen E, Hijdra A, Koelman J, Hart A, Vos P, Verbeek M, de Haan R,
Propac Study Group: Prediction of poor outcome within the first 3 days
of postanoxic coma. Neurology 2006, 66:62–68.
6. Pfeifer R, Borner A, Krack A, Sigusch HH, Surber R, Figulla HR: Outcome after
cardiac arrest: predictive values and limitations of the neuroproteins
neuron-specific enolase and protein S-100 and the Glasgow Coma Scale.
Resuscitation 2005, 65:49–55.
7. Tiainen M, Roine RO, Pettila V, Takkunen O: Serum neuron-specific enolase
and S-100B protein in cardiac arrest patients treated with hypothermia.
Stroke 2003, 34:2881–2886.
8. Martens P, Raabe A, Johnsson P: Serum S-100 and neuron-specific enolase
for prediction of regaining consciousness after global cerebral ischemia.
Stroke 1998, 29:2363–2366.
9. Fogel W, Krieger D, Veith M, Adams H, Hund E, Storch-Hagenlocher B, Buggle
F, Mathias D, Hacke W: Serum neuron-specific enolase as early predictor of
outcome after cardiac arrest. Crit Care Med 1997, 25:1133–1138.
10. Oksanen T, Tiainen M, Skrifvars M, Varpula T, Kuitunen A, Castrén M, Pettilä
V: Predictive power of serum NSE and OHCA score regarding 6-month
neurologic outcome after out-of-hospital ventricular fibrillation and
therapeutic hypothermia. Resuscitation 2009, 80:165–170.
11. Rundgren M, Karlsson T, Nielsen N, Cronberg T, Johnsson P, Friberg H:
Neuron specific enolase and S-100B as predictors of outcome
after cardiac arrest and induced hypothermia. Resuscitation 2009,
80:784–789.
12. Reisinger J, Höllinger K, Lang W, Steiner C, Winter T, Zeindlhofer E, Mori M,
Schiller A, Lindorfer A, Wiesinger K, Siostrzonek P: Prediction of neurological
outcome after cardiopulmonary resuscitation by serial determination of
serum neuron-specific enolase. Eur Heart J 2007, 28:52–58.
13. Bouwes A, Binnekade J, Kuiper M, Bosch F, Zandstra D, Toornvliet A,
Biemond H, Kors B, Koelman J, Verbeek M, Weinstein H, Hijdra A, Horn J:
Prognosis of coma after therapeutic hypothermia: a prospective cohort
study. Ann Neurol 2012, 71:206–212.
14. Steffen IG, Hasper D, Ploner CJ, Schefold JC, Dietz E, Martens F, Nee J,
Krueger A, Jörres A, Storm C: Mild therapeutic hypothermia alters neuron
specific enolase as an outcome predictor after resuscitation: 97
prospective hypothermia patients compared to 133 historical non-
hypothermia patients. Crit Care 2010, 14:R69.
15. Daubin C, Quentin C, Allouche S, Etard O, Gaillard C, Seguin A, Valette X,
Parienti JJ, Prevost F, Ramakers M, Terzi N, Charbonneau P, du Cheyron D:
Serum neuron-specific enolase as predictor of outcome in comatose
cardiac-arrest survivors: a prospective cohort study. BMC Cardiovasc
Disord 2011, 11:48.
16. Štern P, Bartoš V, Uhrová J, Springer D, Vaníčková Z, Tichý V, Průša R, Zima T:
The comparability of different neuron-specific enolase immunoassays
and its impact on external quality assessment system. Am J Physiol
Endocrinol Metab 2007, 15:21–26.
17. Auer J, Berent R, Weber T, Porodko M, Lamm G, Lassnig E, Maurer E, Mayr H,
Punzengruber C, Eber B: Ability of neuron-specific enolase to predict survival
to hospital discharge after successful cardiopulmonary resuscitation. CJEM
2006, 8:13–18.
18. Prohl J, Bodenburg S, Rustenbach S: Early prediction of long-term cognitive
impairment after cardiac arrest. J Int Neuropsychol Soc 2009, 15:344–353.
19. Rech T, Vieira S, Nagel F, Brauner J, Scalco R: Serum neuron-specific enolase
as early predictor of outcome after in-hospital cardiac arrest: a cohort
study. Crit Care 2006, 10:R133.
20. Cronberg T, Rundgren M, Westhall E, Englund E, Siemund R, Rosén I, Widner
H, Friberg H: Neuron-specific enolase correlates with other prognostic
markers after cardiac arrest. Neurology 2011, 77:623–630.
21. Blondin N, Greer D: Neurologic prognosis in cardiac arrest patients
treated with therapeutic hypothermia. Neurologist 2011, 17:241–248.
22. Oddo M, Rossetti A: Predicting neurological outcome after cardiac arrest.
Curr Opin Crit Care 2011, 17:254–259.
23. Nielsen N, Wetterslev J, Cronberg T, Erlinge D, Gasche Y, Hassager C, Horn J,
Hovdenes J, Kjaergaard J, Kuiper M, Pellis T, Stammet P, Wancher M, Wise
MP, Åneman A, Al-Subaie N, Boesgaard S, Bro-Jeppesen J, Brunetti I, Bugge
J, Hingston CD, Juffermans NP, Koopmans M, Koeber L, Langoergen J, Lilja
G, Moeller J, Rundgren M, Rylander C, Smid O, et al: Targeted Temperature
Management at 33°C versus 36°C after Cardiac Arrest. N Engl J Med 2013,
396:2197–2206.
Rundgren et al. BMC Research Notes 2014, 7:726 Page 7 of 7
http://www.biomedcentral.com/1756-0500/7/72624. Nielsen N, Wetterslev J, Al-Subaie N, Andersson B, Bro-Jeppesen J, Bishop G,
Brunetti I, Cranshaw J, Cronberg T, Edqvist K, Erlinge D, Gasche Y, Glover G,
Hassager C, Horn J, Hovdenes J, Johnsson J, Kjaergaard J, Kuiper M,
Langoergen J, Macken L, Martinell L, Martnor P, Pellis T, Pelosi P, Petersen P,
Persson S, Rundgren M, Saxena M, Svensson R, et al: Target temperature
management after out-of-hospital cardiac arrest–a randomized,
parallel-group, assessor-blinded clinical trial–rationale and design.
Am Heart J 2012, 163:541–548.
25. Vos P, Lamers K, Hendriks J, Haaren M, Beems T, Zimmerman C, Geel W, Reus
H, Biert J, Verbeek M: Glial and neuronal proteins in serum predict outcome
after severe traumatic brain injury. Neurology 2004, 62:1303–1310.
26. Mlynash M, Buckwalter M, Okada A, Caulfield A, Venkatasubramanian C,
Eyngorn I, Verbeek M, Wijman C: Serum neuron-specific enolase levels
from the same patients differ between laboratories: assessment of a
prospective post-cardiac arrest cohort. Neurocrit Care 2013, 19:161–166.
27. Cronberg T, Brizzi M, Liedholm L, Rosén I, Rubertsson S, Rylander C, Friberg
H: Neurological prognostication after cardiac arrest-Recommendations
from the Swedish Resuscitation Council. Resuscitation 2013, 84:867–872.
28. Rossetti A, Oddo M, Liaudet L, Kaplan P: Predictors of awakening from
postanoxic status epilepticus after therapeutic hypothermia. Neurology
2009, 72:744–749.
29. Andersen M, Mouritzen C, Gabrielli E: Mechanisms of Plasma Hemoglobin
Clearance after Acute Hemolysis: Studies in Open-Heart Surgical Patients.
Ann Surg 1966, 4:529–536.
30. Stern P, Bartos V, Uhrova J, Bezdickova D, Vanickova Z, Tichy V, Pelinkova K,
Prusa R, Zima T: Performance characteristics of seven neuron-specific
enolase assays. Tumour Biol 2007, 28:84–92.
doi:10.1186/1756-0500-7-726
Cite this article as: Rundgren et al.: Serum neuron specific enolase –
impact of storage and measuring method. BMC Research Notes 2014 7:726.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
